Impressive Clinical Results Show Medtronic, Inc. ENDEAVOR(TM) Drug-Eluting Coronary Stent Provides Significant Long-Term Safety And Efficacy Benefits
PARIS--(BUSINESS WIRE)--May 16, 2006--Prof. Ian Meredith, Principal Investigator of the ENDEAVOR I clinical trial and Professor of Medicine, Monash Medical Centre, Melbourne, Australia, today presented impressive long-term clinical results from the Medtronic (NYSE:MDT - News) ENDEAVOR I and ENDEAVOR II trials at the Paris Course on Revascularization (EuroPCR). Data from the two studies shows that the Endeavor(TM) drug-eluting coronary stent is continuing to provide significant and sustained efficacy and safety performance over time, with low rates of repeat procedures and no observations of late stent thrombosis.